Company Registration Number: 02988368

INTERNATIONAL HEADACHE SOCIETY

(A company limited by guarantee and not having a share capital)

Registered Charity Number: 1042574

REPORT AND ACCOUNTS

Year ended 31 December 2018

INTERNATIONAL HEADACHE SOCIETY

REPORT AND ACCOUNTS - YEAR ENDED 31 DECEMBER 2018

Contents	<u>Page</u>
Report of the Trustees	1-10
Statement of financial activities, including the income and expenditure account – consolidated (Society and subsidiary company)	11
Statement of financial activities, including the income and expenditure account – company (Society only)	12
Consolidated (Society and subsidiary company) balance sheet	13
Company (Society only) balance sheet	14
Statement of cash flow & consolidated Statement of cash flow	15
Notes to the accounts	16-23
Independent auditor's report	24-25

The Trustees present their annual report with the accounts of the Society and its subsidiary company for the year ended 31 December 2018.

Reference and administrative details, Trustees and advisers

Legal status

The International Headache Society (IHS) was founded in 1982 and incorporated as a company limited by guarantee and not having a share capital (company registration number 2988368) in 1994. Its affairs are governed by its Memorandum and Articles of Association. The company was registered as a charity in England and Wales (registered charity number 1042574) in 1995.

Principal and Registered office

4th Floor, Mitre House 44-46 Fleet Street London EC4Y 1BN

Professional advisers

Bankers - Santander UK plc

1st Floor Market Place Derby DE1 3PY

Close Brothers Limited 10 Crown Place

London EC2A 4FT

Schroder Unit Trust Limited

31Gresham Street London EC2V 7QA

Eskmuir Asset Management Ltd

8 Queen Anne Street London W1G 9LD

Solicitors - Wilsons

Steynings House Summerlock Approach

Salisbury Wiltshire SP2 7RJ

Auditor - MHA MacIntyre Hudson

New Bridge Street House 30–34 New Bridge Street

London EC4V 6BJ

Trustees

The Trustees, who act as directors of the company, who have served since 1 January 2018, are as follows:

A Ambrosini	R Jensen	
M Ashina (President-elect)	I Nilsson-Remahl	
M Braschinsky	Mario Peres	
C-S Chung	Patricia Pozo Rosich	
D Dodick (Past-President)	Todd Schwedt	
L Edvinsson (President)	G Terwindt	
S Evers (Honorary Secretary)	WL Thomas (Treasurer)	
B Jenkins		

Structure, governance and management

In common with all limited liability companies, the Society has a board of directors who take overall responsibility. A new Memorandum and Articles of Association was adopted in September 2008 which created a Board of Trustees, who became the directors of the Society.

The day-to-day running of the Society is the responsibility of the Board of Trustees with the assistance of a self-employed Administrative Manager. In addition, there are twenty-one advisory Standing Committees and Special Interest Groups.

The constitution allows for the members in general meeting to elect Honorary life members; seven were elected in 1997 (Eero Hokkanen, James W Lance (since deceased), Frank Clifford Rose (since deceased), Federigo Sicuteri (since deceased), Ottar Sjaastad, Dieter Soyka (since deceased), Marcia Wilkinson (since deceased)) and a further four in 2002 (John Desmond Carroll, Karl Ekbom, Lee Kudrow, Edgard Rafaelli Jnr (since deceased)). From 2005, it was agreed that all Past-Presidents of the Society should be elected as Honorary life members following their leaving the Executive Committee (including retrospectively) and a further seven were elected at this time (Marie-Germaine Bousser, Michel D Ferrari, Ninan T Mathew (since deceased), Jes Olesen, Jean Schoenen, Peer Tfelt-Hansen, K Michael Welch). In 2009 a further two Past-Presidents (Michael A Moskowitz, Fumihiko Sakai) and two recipients of the IHS Recognition for Service Award (Peter J Goadsby, Timothy J Steiner) were elected. In 2011 the Past-President (Hans-Christoph Diener) and a recipient of the IHS Recognition for Service Award (E Anne MacGregor) were elected. In 2013 two recipients of the IHS Recognition for Service Award (Giuseppe Nappi and K Ravishankar) were elected. In 2017 the Past-President (Alan Rapoport) was elected.

IHS offers Junior membership at a reduced rate to Residents and Trainees alternatively within 3 years of obtaining medical doctorate or academic post graduate degree or specialist certification, whichever was obtained latest, or within 6 years of obtaining latest academic degree for other academic groups. Standard members (which includes Honorary and Junior members) are entitled to vote at IHS meetings.

National scientific societies sharing the aims of the IHS can become Affiliate Member Societies of IHS. The representatives of the Affiliate Member Societies join the Advisory Council.

In 2002, Associate membership of IHS was created to assist those professionally interested in headache disorders who are residents of the world's 100 poorest countries to participate in the global discourse on headache via free online access to the journal Cephalalgia which the Society publishes.

Induction and training of Trustees

New Trustees are recruited following elections at the Annual General Meeting. A 'Trustees' Pack' is given to new trustees as part of their induction. Each year there are at least two Board meetings or teleconferences.

Risk management

In June 2004 the Society adopted a formal risk management policy and structure for assessing risk and this was updated in January 2012. The Society supports a systematic approach to risk management that ensures that the risks associated with every activity are assessed, ranked and prioritised. A risk map is produced which is reviewed by the Board of Trustees annually. The Board of Trustees are confident that this ensures that any exposure to risk is identified and that procedures are in place to manage that risk. The principal risks facing the charity relate to the continuance of funding income. The Trustees are confident that this has been addressed.

Objectives and activities

Objects and principal activities

The objects are to relieve sickness and to protect and preserve health in the United Kingdom and elsewhere in the world, including in any one or more of the individual countries of the world. The Society achieves this, in particular, by promoting research into the causes, mechanisms, consequences, diagnosis, prevention, treatment and other aspects of headache and by disseminating the useful results of such research, by advancing the education and raising the awareness of the public of the subjects of headache, its science and management, and by such other ways as the charity through its trustees may from time to time decide. The income and property of the Society are applied solely towards the promotion of its objects.

Aims and objectives

In 2018 the Society aimed to continue its work in promoting headache research and dissemination of knowledge.

The Online Learning and Education Centre, on the IHS website, expanded its resources throughout the year. Two IHS Fellowships and three Short-stay Scholarships were awarded, two Headache Trainees were funded, and IHS supported three students to attend the Danish Master in Headache Disorders course. An IHS Headache Master School was held in Australia, an iHEAD headache academy in the UK, Visiting Professors were sent to two countries to teach and IHS funded a child and adolescent conference in Moldova. Funding was offered to the 7th Asian Regional Consortium for Headache Conference and the Middle East and North African headache meeting. Funding was also offered to the Lifting the Burden campaign to support child and epidemiology studies in Iran and Mongolia. The International Classification of Headache Disorders, 3rd edition, was finalised and published in Cephalalgia, and a set of official IHS Guidelines were published in Cephalalgia. A new open-access IHS journal, Cephalalgia Reports, was launched as a silhouette title to Cephalalgia. The IHS Corporate Roundtable brought together key stakeholders to ensure the future of headache medicine and patient access to new medications. Following on from the Global Patient Advocacy Summit (GPAS) held in Vancouver in 2017, the white paper, the 'Vancouver Declaration' was published in Cephalalgia, and a Global Patient Advocacy Coalition (IHS-GPAC) was formed to act on the many proposals and initiatives from GPAS, and create a strategic plan and blueprint for global implementation.

Activities

Every other year the Society, through its subsidiary company, holds an International Headache Congress (IHC), at which developments and research in the field of headache is discussed (see above). The Society also publishes a professionally acclaimed journal, Cephalalgia, and an extensive Online Learning and Education Centre is hosted on the IHS website. Educating the next generation of headache specialists and teaching in regions where headache specialists are few (Visiting Professor programme) are key objectives, as is raising awareness of headache and migraine worldwide and reducing the associated stigma.

Professional Collaborations

The Society works closely with its Affiliate Member Societies (national societies). In 2018 there were 51 Affiliate Member Societies worldwide. Some of the Affiliate Member Societies offer membership of IHS through their society; these include the American Headache Society, the Italian Neurological Association for Research on Headache, the Australian and New Zealand Headache Society, the Austrian Headache Society, the British Association for the Study of Headache, the Brazilian Headache Society, the Danish Headache Society, the Dutch Headache Society, the Estonian Headache Society, the German Migraine and Headache Society, the Japanese Headache Society, the Latin-American Headache Society, the Italian Headache Society and the Headache Chapter of the Turkish Neurological Society.

IHS (via the IHS Trading Company) hosts the biennial International Headache Congress which is organised in consultation with the national society of the hosting country. Recent congresses have been held in Vancouver, Canada (2017), Valencia, Spain (2015); Boston, USA (2013); Berlin, Germany (2011); Philadelphia, USA (2009); Stockholm, Sweden (2007). The next congresses will be held in Dublin, Ireland, in 2019 and Helsinki, Finland, in 2021.

IHS also collaborates with the World Health Organization on the International Classification of Headache Disorders (ICD-11), and with the International Association for the Study of Pain and the World Federation of Neurology.

Public benefit

In preparing this report the trustees have considered the Charity Commission's general guidance on public benefit.

Through its activities, mostly notably the journals, the congress, the International Classification of Headache Disorders, revised guidelines, worldwide education and the Online Learning and Education Centre, the Society disseminates vital research and educates physicians and headache specialists throughout the world in order that they are better able to understand and treat headache sufferers. Through the IHS-Global Patient Advocacy Coalition the Society raises awareness of headache and migraine and advocates for sufferers worldwide.

Strategic Report

Achievemnts and performance

Dr Stefan Evers reports to the Society as honorary secretary.

This report covers the activities of IHS for the year ended 31 December 2018.

Cephalalgia had another successful year. The 2017 impact factor rose to 3.882; Cephalalgia is ranked 43 out of 197 clinical neurology journals and 76 out of 261 neuroscience journals. Professor Arne May continues as Editor-in-Chief.

An open-access silhouette title to Cephalalgia, Cephalalgia Reports, was launched. The online journal provides an international forum for original research papers, review articles, clinical perspectives, case reports, technical reports and short communications. By the end of 2018 20 articles had been published. All articles are freely available online immediately upon publication.

Membership numbers reduced a little during 2018; at the end of the year there were 1,165 members, 57% of whom were members through their Affiliate Society. Members who did not renew were actively followed up throughout the year and numbers are expected to rise in 2019 when the International Headache Congress (IHC) will be held. There were also 948 Associate Members, specialists living in developing countries who receive free access to Cephalalgia and the IHS website. In 2018 we welcomed a new Affiliate Member Society, the Headache Society Singapore.

In September 2017 the first Global Patient Advocacy Summit (GPAS) was convened. GPAS was a 1-day summit to establish essential global goals for medicine with an emphasis on patient support. Representatives from many of the 50 IHS Affiliate Members were present, plus patient representatives, regulators, partner professional associations and advocacy groups. The output of the summit was a consensus to establish a Global Patient Advocacy Coalition (IHS-GPAC) and to publish a white paper as a blueprint of the strategy for implementing headache patient advocacy efforts around the world. The white paper was published as the Vancouver Declaration in Cephalalgia in November 2018. The IHS-GPAC will develop a unified global strategy and global advocacy toolkits based on the key advocacy goals outlined in the Vancouver Declaration. Steering and Core Committees were established and members met in New York in October 2018 to define the strategy and objectives.

Patient advocacy is a new direction for IHS and will become a major part of the Society's work over the next few years to ensure that migraine and headache are serious disorders that are recognised worldwide and affect around 3 billion of the population globally and contribute around 17% to the global burden of neurologic diseases, with migraine the second most disabling disorder overall. In order to realise this strategy, funding has been sought from industry partners, and the project will be run by an external professional communications agency.

The European Corporate Roundtable brings together industry partners, IHS representatives, patient advocates and a European Medicines Agency representative. The main purpose of the Roundtable is to begin a dialogue between all stakeholders to enhance the efficiency of drug development in the European Union and evaluate/minimise barriers to access to new drugs and devices for appropriate patients. The Corporate Roundtable met in January and July to discuss the future of clinical headache research for the treatment of acute headache episodes and headache prevention by drugs, procedures or devices; common clinical trial outcome measures; how to ensure patient access to new medications; and IHS guidelines both for the conduct of clinical trials and treatment guidelines.

The Standing Committees and Special Interest Groups continued to be active on behalf of the Society.

The society continued to collaborate with the International Association for the Study of Pain and the World Health Organization on the International Classification of Diseases-11, where IHS is represented by Stefan Evers and Shuu-Jiun Wang.

Work on the International Classification of Headache Disorders-3rd edition (ICHD-3) was completed and published in Cephalalgia. An online version of ICHD-3 was developed, and a short version, which is particularly useful for non-experts and primary care, was prepared and posted on the IHS website. Local societies worldwide are translating the classification and translations are currently available in Chinese, German, Korean and Spanish. The Clinical Trials Committee completed work on updating the guidelines on prophylactic treatment of chronic migraine which was published in Cephalalgia.

A fourth European International Headache Academy (iHEAD) was held in London, UK, attracting 69 participants mostly from European countries. The Asian Regional Consortium for Headache (ARCH) held their 7th ARCH conference in Seoul, South Korea, in collaboration with the 16th Asian Oceanian Congress of Neurology. The Child and Adolescent committee held an International Conference on Childhood Headache and a public education meeting in Moldova. IHS funded a Migraine Master Class in Sri Lanka.

The Education committee facilitated an IHS Headache Master School in Australia, which brought together 134 delegates, 76 from Australia and New Zealand, and 58 from neighbouring countries. The Master School programme includes reading and questions before and after the weekend meeting and this formal learning programme is expected to improve headache expertise, care and collaboration between future headache leaders in that region. The committee also organised a secondary headache session during the Migraine Trust International Symposium (MTIS) in London. Representatives of IHS participated in the International Association for the Study of Pain (IASP) World Congress on Pain in Boston in a joint IASP-IHS session. Visiting Professors were sent to lecture at meetings in Colombia and the Baltic region.

Two IHS Fellowships were awarded in 2018, one to a researcher from Iran to study with Dr Arn van den Maagdenberg in the Netherlands, the other to a researcher from Belgium to study with Dr Phillip Holland in the UK. IHS also awarded a joint IHS-American Brain Foundation fellowship to a researcher in Denmark. Two Headache Trainee programme awards enabled young researchers/physicians to spend up to 3 months in major headache centres; one from Egypt visited Professor Peter Goadsby in the UK, the other from Georgia worked with Dr Zaza Katsarava in Germany.

IHS awarded Masters Grants to three young physicians from Spain, Iran and Pakistan to attend the University of Copenhagen Master of Headache Disorders programme, a continuing professional development programme for healthcare professionals.

The Juniors' committee organised the 6th Headache Excellence Tournament during MTIS; the tournament offers juniors a platform to present their data during a short talk and discussion and two winners were voted for by the audience. This is an exceptional experience which has proved very valuable for participants and will continue in future years.

The Juniors' committee also awarded three Short-stay Scholarships to physicians from Colombia, Ukraine and Mongolia. The successful applicants visited three specialist clinics in Spain and Italy for up to 6 weeks and also attended either MTIS or the European Headache Federation Congress. This initiative addresses the need for essential and improved clinics, research and education about headaches and their treatment in developing countries. The aim of the programme is to increase transnational mobility of young researchers living in developing countries by providing grants for short, goal-directed stays in headache centres and research institutions in the country where the biennial IHC or a European congress is being held.

The Electronic Media Committee continued to heighten IHS' profile in social media.

Three non-IHS congresses/courses were offered the opportunity to run under the auspices of IHS during 2018: the IX Congresso Nazionale ANIRCEF, June, Italy; the XVI ASC Course: Advanced training seminar on headaches, March and November, Italy; and the 'Headache Update 2018' held in Mumbai, India.

The Society continued its collaboration with Lifting the Burden, supporting three child and adolescent epidemiology studies in Zambia, Iran and Mongolia.

Carol Taylor continues to provide administrative assistance to the Society and codeinteractive.digital supports the website.

I am grateful to the Trustees, Standing Committees and Special Interest Groups and Affiliate Societies for their activities on behalf of IHS throughout 2018.

No professional fundraisers are used by the charity and the trustees monitor all aspects of fundraising.

Financial review

Investment policy

The Trustees consider social, environmental and ethical considerations when investing. The Society held significant cash reserves as at 31 December 2011 of £1.4m and a decision was made by the Board in early 2012 to invest £500k in specialist quoted charity investments with J P Morgan to generate higher revenue in capital returns.

In September 2016 the J P Morgan products were no longer available and were sold for £643k. In November 2016 £600k was reinvested in four Schroder Unit Trust Funds.

In 2017 it was recommended and subsequently agreed by the Board to invest £250k in the Diversified Property Fund for Charities (DPFC) managed by Eskmuir Asset Management Ltd. This was concluded in August 2017. A further £250k was invested in the DPFC in September 2018.

Any significant surplus cash held by the Society is placed on bank deposit. The Trustees consider this gives a reasonable return at very low risk and allows the flexibility to have easy access to funds at short notice should demands be made on the Society in order for it to achieve its charitable objectives.

The Trustees consider that the investment performance was satisfactory and investment objectives had been met.

Reserves policy

At 31 December 2018 the group's unrestricted funds totalled £2.006.340 (2017: £2.039.858).

Certain of the group's income arises only in alternate years. In addition, grants and donations received can vary significantly from year to year. At this stage in the group's development the Trustees consider it appropriate to maintain a general reserve in the region of two to three times the expected annual expenditure. Should the group's income fall unexpectedly, this general reserve would be used to enable it to plan and execute in good order either a reduction in its activities or an improvement in its income stream.

Financial activities and affairs

As shown in the statement of financial activities on page 11, the group had total income of £1,762,422 in 2018 (2017: £1,973,149) and net increase in funds for the year of £623,963 (2017: £618,123).

The group's income was made up from several sources. Royalty income from the Society's journal Cephalalgia totalled £207,308 (2017: £220,673) and membership fees reached £107,510 (2017: £132,605). In addition, the company received corporate donations of £1,395,395 (2017: £403,566). Of the total corporate donations received, £1,153,579 is restricted funds. Investment income from its investments and bank deposits totalled £52,209 (2017: £35,584).

The group had total expenditure of £1,098,437 in 2018 (2017: £1,385,269). Of the total expenditure in 2018 £496,098 was restricted.

The group's expenditure included governance costs of £6,722 (2017: £9,435), grants and expenditure made in furtherance of the charity's objectives of £126,436 (2017: £136,777), educational development costs including iHEAD London and a Headache Master School in Australia totalled £140,569 (2017: £41,829), costs of its journal, Cephalalgia, of £52,948 (2017: £52,948), committee expenses of £143,395 (2017: £157,628) and support costs of £129,387 (2017: £142,340).

The Trustees are of the opinion that the overall state of affairs of the group and of the company at 31 December 2018 is satisfactory and, in particular, that the group and the company have sufficient assets available to enable them to adequately fulfil their obligations

Grants and donations

All of the Society's resources are dedicated to the achievement of its objectives. There are occasions where it is appropriate to make grants (and to provide support) to individuals and institutions towards the costs of activities and events undertaken for reasons complementary to the Society's objectives. In addition, there are cases where other institutions working on a similar agenda are better placed to achieve the Society's objectives. In those cases, the Society may choose to donate some of its financial resources thereto. The Board of Trustees considers all grants and donations in detail prior to giving approval (or otherwise).

Plans for future periods

IHS will work to strengthen existing partnerships and establish new strategic relationships which will allow the society to extend its educational reach and influence regional, national, and global policy makers that will facilitate drug development, remove barriers to care, and improve access to new and emerging therapies.

Work will begin to realise the IHS-GPAC objectives. The vision of IHS-GPAC is to create a world in which migraine and other headache disorders are understood and those who suffer receive optimal care. The coalition aims to develop a unified global strategy for headache patient advocacy and global toolkits dedicated to the key advocacy goals outlined in the Vancouver Declaration. The strategy will focus on development and rollout of a migraine employee support initiative to bring tangible improvements to patient lives. The main objectives will include empowering employees to seek treatment and improve their wellbeing, reducing stigma associated with migraine in the workplace, and ensuring support for those impacted by migraine in the workplace. The professional communications company will work closely with the Steering and Core Committees and professional advisors to identify potential global companies who will engage with IHS-GPAC and implement migraine wellness and awareness programmes within their companies globally.

In relation to IHS-GPAC, IHS will forge closer relations with the World Health Organization (WHO) and the World Federation of Neurology (WFN). WFN has dedicated World Brain Day 2019 to migraine, and joint summits at the IHS International Headache Congress (IHC) 2019 in September and the WFN World Congress of Neurology (WCN) in October. A press conference is also scheduled to take place at WCN to which representatives of the engaged companies will be invited.

IHS will continue to seek representation in the developing world through the Affiliate Societies in these regions and fund educational activities. Associate Membership will be actively promoted through the Affiliate Societies at their meetings and courses to further highlight the work of the society and increase knowledge and headache research in these regions.

IHS is already represented in Asia with the Asian Regional Committee for Headache (ARCH), and will continue to support activities in this region and try to promote headache research among the general neurologists. IHS will also continue to support our Asian colleagues in a partnership with the World Health Organization (Western Pacific Regional Office) in a major study evaluating the workplace burden of headache disorders in Asia.

IHS will continue to expand our partnership with IASP and representatives from IHS will present during a joint IHS-IASP symposium during the IHC 2019 in Dublin in September 2019.

During 2019 IHS will organise two European Corporate Roundtable meetings, the first one having been held in April 2019.

A slide kit to accompany the International Classification of Headache Disorders, 3rd edition (ICHD-3) will be developed and disseminated through the IHS Affiliate Member Societies and posted on the IHS website. A classification on facial pain, developed in collaboration with the Orofacial and Head Pain Special Interest Group (OFHP SIG) of the International Association for the Study of Pain (IASP), the International Network for Orofacial Pain and Related Disorders Methodology (INfORM), the American Academy of Orofacial Pain (AAOP) will be completed and published. The International Classification of Diseases, 11th revision (ICD-11) which includes a chapter on chronic pain prepared by IASP and IHS representatives, will be finalised and field tested for a 2–3-year period before final publication.

The Clinical Trials committee will publish two guidelines, on controlled trials of acute treatment of migraine, and controlled trials of preventive treatment of migraine in children and adolescents. The committee will begin work on guidelines on preventive drugs in episodic migraine, devices in episodic migraine, and idiopathic intracranial hypertension. The new guidelines will be reviewed by IHS members and the Corporate Roundtable members prior to submission to Cephalalgia.

In 2019 IHS will continue with our educational activities.

IHS will organise a 5th International Headache Academy (iHEAD) in September. The programme will include young senior neurology residents, headache medicine fellows and MD and/or PhD headache researchers, some who will have attended previous iHEADs, and new junior specialists. As iHEAD 2019 will be held immediately before the IHC, IHS international delegates will also be invited to attend.

A Headache Trainee programme to facilitate attendance of physicians from developing countries or countries in transition to visit a specialised headache institution abroad and actively increase knowledge on headache disorders and specialised headache management will be offered. Visiting Professors will continue to visit regions where there is an unmet need for headache education.

The Education Committee will continue work on updating the Core Curriculum for Neurologists to enable it to be utilised, with local modifications, in various countries, undergraduate and postgraduate training programmes. The Committee will aim to work closely with the Affiliate Societies to generate more interaction on educational programmes.

The Child and Adolescent Committee will organise a childhood headache symposium in Turkey with international expert specialists covering common childhood headache disorders and their treatment.

Up to two Fellowships worth £50,000 each will be offered to junior IHS members for either clinical or basic research, or a combination of both. Three peri-IHC Short-Stay Scholarships will be awarded to young physicians from developing countries.

IHS will offer funding for research grants through an open application for proposal to all IHS members. The grants will be offered for any kind of research acceptable, but the research should further the mission and goals of the Society and preferably involve collaborations amongst investigators from multiple institutions and countries.

The Society will continue to closely interact with its international Affiliate Member Societies, encouraging their members to join IHS at a preferential rate through their national society and gathering educational materials for the Online Learning and Education Centre in multiple languages.

The Electronic Media Committee will continue to forge relationships with doctors and researchers all over the world, and actively promote IHS activities through social media platforms.

The 18th IHC will be held in Dublin, Ireland, in September 2019. Headache specialists, nurses and juniors from all over the world will unite for an advanced scientific programme including teaching courses, scientific sessions featuring renowned headache specialists, debates and poster presentations, and take advantage of a platform for the exchange of the latest information, treatments, care, and research into headache.

During 2019 work will begin on preparations for the IHC 2021 to be held in Helsinki, Finland, and preliminary work on venue selection and committees for the IHC 2023.

Elections for the President-elect and three new elected trustees will be held during the Annual General Meeting.

Recognising the need to mentor future leaders and minority groups in headache medicine, IHS will continue development of a Headache Emerging Leadership Programme and a Women's Leadership Forum.

Other matters

Indemnity insurance

The charity maintains a Trustees Indemnity Insurance policy with Case Executive Insurance, covering the Trustees against certain liability claims.

Trustees' responsibilities

The Trustees are responsible for preparing the accounts in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice.

The Trustees are required to prepare accounts for each financial year which give a true and fair view of the state of affairs of the group and of the company and of their income and expenditure for that period. In preparing those accounts, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Statement of Recommended Practice Accounting and Reporting by Charities;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the accounts; and
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the group and the company will continue in operation.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the group and of the company and to enable them to ensure that the accounts comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Statement of disclosure to the auditors

As far as the Trustees are aware, there is no relevant audit information of which the company's auditors are unaware. All of the Trustees have taken all steps that they ought to as directors in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

Auditors

MHA MacIntyre Hudson were appointed as auditors at the Annual General Meeting held in September 2018 for the year ended 31 December 2018. A resolution to re-appoint the auditors will be proposed at the Annual General Meeting in September 2019.

In approving the Trustees Annual Report, we also approve the Strategic Report included therein, in our capacity as company directors.

Approved by the Trustees on 04 September 2019 and signed on its behalf by:-

Lars Edvinsson PRESIDENT

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT CONSOLIDATED (SOCIETY & SUBSIDIARY COMPANY)

FOR THE YEAR ENDED:		31 DECEMBER 2018			2017
		Unrestricted	Restricted		
	<u>Note</u>	funds	<u>funds</u>	<u>Total</u>	<u>Total</u>
INCOME	1d)				
<u>Donations</u>	/	241,816	1,153,579	1,395,395	403,566
Charitable activities		,		, ,	,
Income from journal		207,308	-	207,308	220,673
Membership fees receivable from individuals		107,510	-	107,510	132,605
Other trading activities					
Turnover of trading subsidiary	2	-	-	-	1,180,721
<u>Investments</u>					
Bank interest receivable & dividends		52,209	-	52,209	35,584
Total		608,843	1,153,579	1,762,422	1,973,149
EXPENDITURE	1e)				
Raising funds	10)				
Expenditure incurred by trading subsidiary	2	551	_	551	833,912
Charitable activities	3	592,735	496,098	1,088,833	531,521
Other		,	,	, ,	, ,
Loss on exchange		9,053	-	9,053	19,836
Total Expenditure		602,339	496,098	1,098,437	1,385,269
Net income / (expenditure)		6,504	657,481	663,985	587,880
Net (losses) on investments					
Realised & Unrealised Investment loss / gain	9	(40,022)	-	(40,022)	30,243
Net movement in funds		(33,518)	657,481	623,963	618,123
Reconciliation of funds					
Total funds brought forward		2,039,858	78,374	2,118,232	1,500,109
Total funds carried forward		£ 2,006,340	735,855	2,742,195	2,118,232

All incoming resources and resources expended derive from continuing activities.

COMPANY (SOCIETY ONLY)

FOR THE YEAR ENDED:		31 DECEMBER 2018			2017
	_	Unrestricted	Restricted		
]	<u>Note</u>	funds	<u>funds</u>	<u>Total</u>	<u>Total</u>
INCOME	1d)				
Donations Donations	14)	241,816	1,153,579	1,395,395	403,566
Charitable activities		,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,
Income from journal		207,308	-	207,308	220,673
Membership fees receivable from individuals		107,510	-	107,510	132,605
Other trading activities					
Charitable donation - I. H. S. Trading Company	/ Ltd	-	-	-	324,563
<u>Investments</u>					
Bank interest receivable & dividends	_	52,099	-	52,099	35,584
Total Income	_	608,733	1,153,579	1,762,312	1,116,991
EXPENDITURE	1c)				
Raising funds		-	-	-	-
Charitable activities	3	591,935	496,098	1,088,033	530,208
<u>Other</u>					
Loss on exchange		-	-	-	-
Total Expenditure	_	591,935	496,098	1,088,033	530,208
p	-				
Not income //oursenditure)		40.700	CE7 404	074 070	E00 700
Net income / (expenditure)		16,798	657,481	674,279	586,783
Net (losses) on investments					
Realised & Unrealised Investment loss / gain	n	(40,022)	-	(40,022)	30,243
Net movement in funds	_	(23,224)	657,481	634,257	617,026
Pagangiliation of funds		•			
Reconciliation of funds					
Total funds brought forward	_	2,039,858	78,374	2,118,232	1,501,206
Total funds carried forward	£	2,016,634	735,855	2,752,489	2,118,232

All incoming resources and resources expended derive from continuing activities.

CONSOLIDATED (SOCIETY AND SUBSIDIARY COMPANY) BALANCE SHEET

		31 DECEMBER 2018		2017	
	<u>Note</u>				
Fixed assets					
Tangible assets	8		4		5
Mixed motive investments	9		1,111,371		901,393
			1,111,375		901,398
Current assets					
Debtors	10	289,314		581,450	
Cash at bank		2,070,460		816,994	
		0.050.774		4 000 444	
		2,359,774		1,398,444	
<u>Deduct</u> : Creditors: amounts falling					
due within one year	11	728,954		181,610	
Net current assets			1,630,820		1,216,834
Total assets less current liabilities			£ 2,742,195		2,118,232
Funds	12				
Unrestricted					
General fund			617,166		650,133
Non-charitable trading fund			1,324,174		1,324,725
Designated fund			65,000		65,000
			2,006,340		2,039,858
Restricted			735,855		78,374
			£ 2,742,195		2,118,232

Approved and authorised for issue by the trustees on 4 September 2019 and signed on their behalf by:-

L Edvinsson Mrs W L Thomas
Trustee Trustee

COMPANY (SOCIETY ONLY) BALANCE SHEET

BALANCE SHEET		31 DECEMBER 2018		ER 2018	2017	
	<u>Note</u>					
Fixed assets						
Tangible assets	9			4		5
Mixed motive investments	10			1,111,372		901,394
				1,111,376		901,399
Current assets						
Debtors	11	592,471			645,371	
Cash at bank		1,760,514			737,956	
		2,352,985			1,383,327	
<u>Deduct</u> : Creditors: amounts falling						
due within one year	12	711,872	1		166,494	
Net current assets				1,641,113		1,216,833
Total assets less current liabilities			£	2,752,489		2,118,232
Funds						
Unrestricted						
General fund				1,951,634		1,974,858
Designated fund			_	65,000		65,000
				2,016,634		2,039,858
Restricted			_	735,855		78,374
			£	2,752,489		2,118,232

Approved and authorised for issue by the trustees on 4 September 2019 and signed on their behalf by:-

L Edvinsson Mrs W L Thomas
Trustee Trustee

Company Registration Number: 2988368

STATEMENT OF CASH FLOW & CONSOLIDATED CASH FLOW FOR YEAR ENDING 31 DECEMBER 2018

		Grou	ip	Company		
	<u>Note</u>	2018 £	2017 £	2018 £	2017 £	
Cash generated in operating activities	16	1,451,257	209,959	1,220,459	246,550	
Cash flows from investing activities						
Investment income		52,209	35,584	52,099	35,584	
Sale of Investments		-	-	-	-	
Purchase of Investments		(250,000)	(250,000)	(250,000)	(250,000)	
(Decrease) / Increase in cash in	year	1,253,466	(4,457)	1,022,558	32,134	
Cash at the beginning of the year		816,994	821,451	737,956	705,822	
Casth at the end of the year		2,070,460	816,994	1,760,514	737,956	

NOTES TO THE ACCOUNTS - 31 DECEMBER 2018

1. Accounting policies

a) General information and basis of preparation

The International Headache Society is a charitable company, limited by guarantee, incorporated in England and Wales. The address of the registered office is on the Administrative details page. The Financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) Update Bulletin 1 – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. The Society constitutes a public benefit entity as defined by FRS 102.

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are presented in sterling which is the functional currency of the charity and rounded to the nearest pound.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

b) Going concern

The financial statements are prepared on a going concern basis as the Trustees believe that no material uncertainties exist. The trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the Society to be able to continue as a going concern.

c) Consolidation

The Statement of Financial Activities and Balance Sheet consolidate the financial statements of the company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

d) Income and endowments from:

Grants, donations and similar income are accounted for as received, except for donations made to the International Headache Society by its subsidiary company which are accounted for in the period to which those donations relate. All other income is brought to credit in the accounts in the period to which it relates. All incoming resources are allocated between unrestricted and restricted funds as appropriate. Members income received in advance of renewal are included in creditors, being deferred income.

e) Expenditure on:

All resources expended are taken into account on the accruals basis. All resources expended are directly included in the applicable category of resources expended, allocated between unrestricted and restricted funds as appropriate and include irrecoverable input VAT, where relevant.

f) International Headache Congress (IHC)

The next IHC will be held in Dublin, Ireland, September 2019. The accounts of the IHC 2019 will be finalised in the year ending 31 December 2019.

g) Tangible fixed assets

Tangible fixed assets exceeding £250 are capitalised and are stated in the balance sheet at cost less depreciation. Depreciation is provided on the tangible fixed assets at 25% per annum on written down value so as to write off the cost of the assets over their estimated useful working lives.

h) Foreign currency transactions

Assets and liabilities in foreign currencies are translated into sterling at the rate of exchange ruling at the balance sheet date. Income and expenditure in foreign currencies is translated into sterling at the exchange rate ruling at the date of each transaction. Profit/(losses) on exchange are credited/(charged) in the statement of financial activities.

NOTES TO THE ACCOUNTS - 31 DECEMBER 2018 (continued)

i) Funds

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Society and which have not been designated for other purposes.

j) Designated and restricted funds

The Contingency fund is a designated fund set up by the Society to provide for future unforeseen expenditure. The Society's restricted funds are the Chronic Migraine Guidelines fund, representing grants received towards the costs of creating guidelines for controlled trials of prophylactic treatment of chronic migraine in adults, the Core Curriculum fund, representing a grant received towards the cost of developing a core curriculum of education for neurologists and an Online Education fund, funded by Pfizer and Allergan. The IASP/IHS joint meeting fund is restricted to use on IASP and IHS meetings.

The GPAC restricted fund is solely for the purpose of delivering the Global Patient Advocacy Coalition. The origins of the GPAC initiative emerged from the September 2017 Global Patient Alliance Summit (GPAS) held in Vancouver, Canada. GPAC aims to unify stakeholders to establish a centralized global advocacy strategy and resources with tools for operations and monitoring at the local level.

k) Investment

The Society's investment in its subsidiary company is included in fixed assets at cost.

Taxation

As a registered charity the Society is generally not liable to taxation on its surplus or capital gains. It is not, however exempt from value added tax. Irrecoverable value added tax is included in the cost of those items to which it relates. The subsidiary donates all profits, as a distribution, to the parent charity, and no taxable income arises.

m) Grants

Applications are received for grants, for example for assisting Junior members with travel costs to attend IHCs, and these are formally authorised by the Board and paid out on an incurred basis on production of valid documentation.

n) Financial instruments

The Society only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transactional value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

o) Judgements and key sources of estimation uncertainty

No significant judgements or estimates have been made by management in preparing these financial statements other than in the consideration of useful lives of tangible fixed assets. The trustees consider that the useful lives of assets are fairly stated.

p) Related party transactions

As disclosed in Note 2 the Society has one wholly owned subsidiary company, I. H. S. Trading Company Ltd. During the year ending 31 December 2018 I. H. S. Trading Company Ltd made a donation to the Society of £nil (2017: £324,563). As at 31 December 2018 I. H. S. Trading Company Ltd owed The Society £476,122 (2017: £476,122).

NOTES TO THE ACCOUNTS - 31 DECEMBER 2018 (Continued)

2. Subsidiary company's trading activities

The Society has one wholly owned subsidiary company, I. H. S. Trading Company Ltd (see Note 9). That company was incorporated on 1 June 2000 and commenced its activity, the organization of conferences, on 1 January 2001. The Society has owned all of the company's share capital since it was incorporated. The company donates its taxable profits, where applicable, to the Society. A summary of the company's trading results is shown below. Audited accounts for the company have been filed with the Registrar of Companies.

Profit and loss account		<u>2018</u>	<u>2017</u>
Turnover		-	1,180,721
Bank interest		110	-
Expenditure			
Cost of sales in relation to IHC		-	833,438
Other administrative costs		551	474
Bank charges		-	-
*		551	833,912
Deduct: Governance / Audit fees		800	1313
Less: Any foreign exchange movements		9,053	19,836
Deduct: Charitable donation payable to the Society			324,563
(Loss) /profit on ordinary activities before taxation		(10,294)	1,097
Taxation		<u>-</u>	
(Loss) /profit on ordinary activities after taxation	£	(10,294)	1,097

At 31 December 2018 the company had a surplus of capital and reserves of £1 (2017 - £1).

^{*} Note: The expenditure included above has been allocated on the SOFA as 'Expenditure incurred by subsidiary'. Audit fees which have been allocated to 'Charitable activities'

NOTES TO THE ACCOUNTS - 31 DECEMBER 2018 (Continued)

	Unrestricted funds	Restricted funds	2018 <u>Total</u>	2017 <u>Total</u>
3. Charitable activities				
Group and company				
Grants etc. payable in furtherance of the				
charity's objects (see Note 4)	126,436	-	126,436	136,777
Education development (including Visiting Professors, iHEAD, Headache Trainee Programme etc)	140,569	-	140,569	41,829
Trustees, standing committees and special interest groups - travel and other expenses (inc. GPAS / 7th ARCH)	143,395	-	143,395	157,628
Costs of journal	52,948	-	52,948	52,947
Support costs (see Note 5)	129,387	-	129,387	142,340
GPAC	-	496,098	496,098	-
	592,735	496,098	1,088,833	531,521
Grants etc. payable in furtherance of the charity's objects Group and company Grants and donations etc				
IHS 2018 Research Fellowships	100,035	-	100,035	100,026
Miscellaneous discretionary expenditure	-	-	-	-
Short Stay Scholarships	16,401	-	16,401	15,783
Travel grants	10,000		10,000	20,968
	126,436		126,436	136,777

Of the total above, £ nil (2017 - £ nil) was payable to institutions and £126,436 (2017 - £136,777) was payable to individuals.

NOTES TO THE ACCOUNTS - 31 DECEMBER 2018 (Continued)

	Unrestricted <u>funds</u>	Restricted funds	2018 <u>Total</u>	2017 <u>Total</u>
5. <u>Support costs</u>				
Group and company				
Administrator's fees and Financial Support	109,403	-	109,403	106,092
Membership administration	7,031	-	7,031	5,785
Travel and meetings expenses	714	-	714	1,286
Website running costs	625		625	8,124
Communication/Stationery costs	2,873		2,873	3,093
Bank and credit card charges	1,968	-	1,968	3,754
Sundry expenses	50	-	50	4,769
Depreciation	1	-	1	2
Governance (see note 6)	6,722		6,722	9,435
	129,387		129,387	142,340
6. Governance costs				
Group and company				
Travel and meeting expenses	1,356	-	1,356	3,709
Auditor's remuneration	5,283	-	5,283	5,700
Legal, professional and consultancy fees	83		83	26
	6,722		6,722	9,435

No staff are directly employed by the charity.

Company only auditor's remuneration amounted to £4,500 (2017: £4,400).

NOTES TO THE ACCOUNTS - 31 DECEMBER 2018 (Continued)

	Unrestricted <u>funds</u>	Restricted funds	2018 <u>Total</u>	2017 <u>Total</u>
7. <u>Taxation</u>				
Deferred tax charge/(credit)	£			
The deferred tax charge/(credit) relates to a deforward.	crease/(increase) ii	n the subsidiary o	company's tax los	ses carried
8. Tangible fixed assets: Group and company				
Furniture and equipment				
Cost At 1 January 2018 and 31 December 2018			£ 283	
Depreciation At 1 January 2018 Charge for the year		_	278 1	
At 31 December 2017		_	279	
Net book value, 31 December 2018		£ =	4	
Net book value, 31 December 2017		£	5	
The tangible fixed assets are used wholly for g	eneral administration	on purposes.		
9. Mixed motive investments: Group		_	2018	2017
Minard marking investments (and haland			£	£
Mixed motive investments (see below)			1,111,371	901,393
Investment in subsidiary company, at cost		_	1	1
Total Investments		=	1,111,372	901,394
The investment in subsidiary company represe Ltd, a company registered in England and Wal Details of the subsidiary are included in note 2	les, company regis	tration number : 0)4008927.	ng Company
Mixed motive investments (managed by Schro	ders and Eskmuir)		£	£
Market Value at 1 January 2018			901,393	621,150
Acquisitions at cost			250,000	250,000
Disposals at opening market value			-	-
Net gains on revaluation			(40,022)	30,243
Market value at 31 December 2018		=	1,111,371	901,393
Historic cost at 31 December 2018		-	1,100,000	850,000

NOTES TO THE ACCOUNTS - 31 DECEMBER 2018 (Continued)

	Group			<u>up</u>	<u>Company</u>		
		<u>2018</u>		<u>2017</u>	<u>2018</u>	<u>2017</u>	
10. <u>Debtors</u>							
Amount owed by subsidiary company		-		-	476,122	476,122	
Other debtors		280,273		492,966	107,308	120,673	
Prepayments and accrued income		9,041		88,484	9,041	48,576	
	£	289,314	. –	581,450	592,471	645,371	
	=		=				
11. Creditors: amounts falling due within one year							
Membership fees received in advance		33,256		20,721	33,256	20,721	
Other creditors		690,198		155,189	674,116	141,373	
Accruals and deferred income	_	5,500		5,700	4,500	4,400	
	£	728,954	=	181,610	711,872	166,494	
		As at		<u>Total reso</u>	ources	As at	
12. <u>Funds</u>		01.01.18		Incoming	<u>Outgoing</u>	31.12.18	
Group only							
Unrestricted							
General fund		650,133		568,821	(601,788)	617,166	
Non-charitable trading fund		1,324,725		-	(551)	1,324,174	
Designated							
Contingency fund	_	65,000	_	-		65,000	
Total unrestricted funds	_	2,039,858		568,821	(602,339)	2,006,340	
Restricted							
Chronic Migraine Guidelines fund		28,153		-	-	28,153	
Core Curriculum fund		9,001		-	-	9,001	
GPAC fund		-		1,153,579	(496,098)	657,481	
Online Education fund		40,530		-	-	40,530	
IASP/IHS Joint Meeting fund	_	690	_	-		690	
Total restricted funds	_	78,374	_	1,153,579	(496,098)	735,855	
Total funds	£	2,118,232	=	1,722,400	(1,098,437)	2,742,195	
				Unrestricted	Restricted		
Analysis of net assets between funds				<u>funds</u>	<u>funds</u>	<u>Total</u>	
Fund balances at 31 December 2018							
are represented by:-							
Tangible fixed assets				4	-	4	
Quoted Investments				1,111,371		1,111,371	
Current list little				1,623,919	735,855	2,359,774	
Current liabilities			_	(728,954)		(728,954)	
			£	2,006,340	735,855	2,742,195	

Details of restricted funds are given in the notes to the accounts j).

NOTES TO THE ACCOUNTS - 31 DECEMBER 2018 (Continued)

13. Members' liability

The liability of the members is restricted to £1 per member. This liability extends for one year after membership ceases.

14. Material incoming resources

The major sources of material incoming resources are corporations and individuals involved in the medical profession.

15. Trustees' remuneration and expenses

Trustees do not receive any remuneration from the Society.

Trustees are reimbursed expenses necessarily incurred on behalf of the Society. These expenses, which are included in the appropriate categories of resources expended, totalled £38,757 during the year ended 31 December 2018 (2017: £9,917) and were reimbursed to 15 (2017- 12) trustees for travel expenses.

16. Reconciliation of net movements in funds to net cash flow for operating activities

	<u>Group</u>		<u>Company</u>	
	2018	2017	2018	2017
	£	£	£	£
Net movement in funds	623,963	618,123	634,257	617,026
Add back in depreciation charge	1	2	1	2
Add Realised/Unrealised investment (Gains)/Losses	40,022	(30,243)	40,022	(30,243)
Deduct : investment income	(52,209)	(35,584)	(52,099)	(35,584)
Decrease / (increase) in debtors	292,136	(411,328)	52,900	(359,524)
Increase / (decrease) in creditors	547,344	68,989	545,378	54,873
Net cash generated in operating activities	1,451,257	209,959	1,220,459	246,550